UA107675C2 - Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом - Google Patents

Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом

Info

Publication number
UA107675C2
UA107675C2 UAA201204585A UAA201204585A UA107675C2 UA 107675 C2 UA107675 C2 UA 107675C2 UA A201204585 A UAA201204585 A UA A201204585A UA A201204585 A UAA201204585 A UA A201204585A UA 107675 C2 UA107675 C2 UA 107675C2
Authority
UA
Ukraine
Prior art keywords
treatment
thienyl
oxy
phenyl
amino
Prior art date
Application number
UAA201204585A
Other languages
English (en)
Ukrainian (uk)
Inventor
Marc Payton
Richard Kendall
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA107675(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UA107675C2 publication Critical patent/UA107675C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201204585A 2009-09-11 2010-09-09 Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом UA107675C2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24152709P 2009-09-11 2009-09-11
PCT/US2010/048247 WO2011031842A1 (en) 2009-09-11 2010-09-09 N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Publications (1)

Publication Number Publication Date
UA107675C2 true UA107675C2 (xx) 2015-02-10

Family

ID=43216900

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201204585A UA107675C2 (xx) 2009-09-11 2010-09-09 Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом

Country Status (34)

Country Link
US (1) US20120028917A1 (ru)
EP (2) EP2475368B1 (ru)
JP (1) JP5851403B2 (ru)
KR (1) KR20120082896A (ru)
CN (1) CN102869361A (ru)
AU (1) AU2010292225C1 (ru)
BR (1) BR112012008325A2 (ru)
CA (1) CA2773838C (ru)
CL (1) CL2012000640A1 (ru)
CR (1) CR20120171A (ru)
DK (1) DK2475368T3 (ru)
EA (1) EA020526B1 (ru)
ES (1) ES2528485T3 (ru)
HK (1) HK1205457A1 (ru)
HR (1) HRP20150104T1 (ru)
HU (1) HUE024568T2 (ru)
IL (1) IL218569A0 (ru)
MA (1) MA33658B1 (ru)
ME (1) ME02048B (ru)
MX (1) MX2012003041A (ru)
NZ (1) NZ598758A (ru)
PE (1) PE20120895A1 (ru)
PH (1) PH12012500504A1 (ru)
PL (1) PL2475368T3 (ru)
PT (1) PT2475368E (ru)
RS (1) RS53807B1 (ru)
SG (1) SG179102A1 (ru)
SI (1) SI2475368T1 (ru)
SM (1) SMT201500028B (ru)
TN (1) TN2012000110A1 (ru)
TW (1) TW201121956A (ru)
UA (1) UA107675C2 (ru)
WO (1) WO2011031842A1 (ru)
ZA (1) ZA201202472B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2854811A1 (en) * 2012-05-31 2015-04-08 Amgen Inc. Use of amg 900 for the treatment of cancer
CN103664737A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
WO2015046783A1 (en) 2013-09-30 2015-04-02 Korea Institute Of Radiological & Medical Sciences Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising hrp-3 inhibitor
EA202092456A3 (ru) 2013-11-11 2021-09-30 Эмджен Инк. Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
KR20160087902A (ko) * 2013-12-03 2016-07-22 암젠 인크 N-(4-((3-(2-아미노-4-피리미디닐)-2-피리디닐)옥시)페닐)-4-(4-메틸-2-티에닐)-1-프탈라진아민 염의 약제학적으로 허용가능한 결정형 및 이의 용도
CA2940237C (en) * 2014-02-21 2023-03-07 Frost Biologic, Inc. Antimitotic amides for the treatment of cancer and proliferative disorders
BR112018071023A2 (pt) * 2016-04-15 2019-02-05 Felicitex Therapeutics Inc combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose
ES2905676T3 (es) 2017-05-22 2022-04-11 Amgen Inc Inhibidores de KRAS G12C y métodos para su uso
CN111051306B (zh) 2017-09-08 2023-01-03 美国安进公司 Kras g12c的抑制剂及其使用方法
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
CA3100390A1 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CN114144414B (zh) 2019-05-21 2025-11-07 美国安进公司 固态形式

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178318A1 (en) * 2003-07-03 2006-08-10 Shubha Anand Use of aurora kinase inhibitors for reducing the resistance of cancer cells
DK1984353T3 (en) 2006-01-23 2016-03-14 Amgen Inc Aurorakinasemodulatorer and method of use
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
CN101405282B (zh) * 2006-01-23 2015-03-25 安姆根有限公司 极光激酶调节剂和使用方法
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal

Also Published As

Publication number Publication date
ZA201202472B (en) 2012-12-27
EA201270383A1 (ru) 2013-04-30
PL2475368T3 (pl) 2015-05-29
SI2475368T1 (sl) 2015-03-31
EP2818170A1 (en) 2014-12-31
JP2013504582A (ja) 2013-02-07
AU2010292225C1 (en) 2013-06-27
DK2475368T3 (en) 2015-03-09
SMT201500028B (it) 2015-03-05
HUE024568T2 (hu) 2016-02-29
PT2475368E (pt) 2015-02-10
HK1205457A1 (en) 2015-12-18
ES2528485T3 (es) 2015-02-10
BR112012008325A2 (pt) 2017-08-29
EA020526B1 (ru) 2014-11-28
NZ598758A (en) 2013-12-20
RS53807B1 (sr) 2015-06-30
HRP20150104T1 (xx) 2015-03-13
TN2012000110A1 (en) 2013-09-19
AU2010292225A1 (en) 2012-04-12
TW201121956A (en) 2011-07-01
CN102869361A (zh) 2013-01-09
PH12012500504A1 (en) 2015-04-29
CA2773838A1 (en) 2011-03-17
AU2010292225B2 (en) 2012-12-13
CL2012000640A1 (es) 2012-09-21
JP5851403B2 (ja) 2016-02-03
HK1173655A1 (en) 2013-05-24
IL218569A0 (en) 2012-05-31
EP2475368B1 (en) 2014-12-17
US20120028917A1 (en) 2012-02-02
MX2012003041A (es) 2012-06-27
EP2475368A1 (en) 2012-07-18
SG179102A1 (en) 2012-04-27
MA33658B1 (fr) 2012-10-01
KR20120082896A (ko) 2012-07-24
CR20120171A (es) 2012-08-09
CA2773838C (en) 2016-05-31
EP2818170B1 (en) 2018-12-05
PE20120895A1 (es) 2012-08-19
ME02048B (me) 2015-05-20
WO2011031842A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
EA201270383A1 (ru) Применение n-(4-((3-(2-амино-4-пиримидинил)-2-пиридинил)окси)фенил)-4-(4-метил-2-тиенил)-1-фталазинамина для лечения резистентного к антимитотическому агенту рака
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
UA94129C2 (ru) Соединения для ингибирования митоза
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
AU2011297889A8 (en) Pharmaceutically active compounds as Axl inhibitors
MX2012013197A (es) Inhibidores de indazol de cinasa.
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
EA200971115A1 (ru) Новые ингибиторы обратной транскриптазы вич
EA201001687A1 (ru) Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 )
WO2009155121A3 (en) Inhibitors of pi3 kinase
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
UA108369C2 (ru) Пиролопиримидины как ингибиторы cdk4 / 6
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
MY150214A (en) Kinesin inhibitors as cancer therapeutics
ATE542800T1 (de) Kinasehemmer und ihre anwendungsverfahren
EA201391629A1 (ru) Ингибиторы цсж-1r для лечения опухолей головного мозга
MX2014005715A (es) N-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]- benzamida para el tratamiento de leucemia mielogenosa cronica.
ATE548364T1 (de) Aminopyrazolkinasehemmer
GEP20146025B (en) Chromenone derivatives as trpv3 antagonists
MY150776A (en) Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria
MX2018001306A (es) Compuestos de 4-(3-pirazolilamino)-bencimidazol y su uso como inhibidores jak1.